Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-05

AUTHORS

Vitaly Margulis, Christopher G. Wood, Eric Jonasch, Surena F. Matin

ABSTRACT

Cytoreductive nephrectomy (CN) has an established role against metastatic renal cell carcinoma (mRCC) in properly selected patients and offers a survival advantage when performed prior to cytokine therapy. With the emergence of new, effective targeted molecular therapies for mRCC, well-designed prospective trials are needed to clarify the biologic effects of CN to determine when and for whom CN should be performed in the context of targeted systemic therapy. Consequently, a thorough characterization of the systemic effects afforded by CN is imperative for developing individualized treatment strategies that effectively address the underlying biology of mRCC while maximizing patient quality of life during therapy. Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy. More... »

PAGES

253

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11912-008-0038-3

DOI

http://dx.doi.org/10.1007/s11912-008-0038-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033049449

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18765156


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nephrectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "familyName": "Margulis", 
        "givenName": "Vitaly", 
        "id": "sg:person.0700013535.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700013535.70"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Jonasch", 
        "givenName": "Eric", 
        "id": "sg:person.01172764022.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172764022.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Unit 1373, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, Unit 1373, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matin", 
        "givenName": "Surena F.", 
        "id": "sg:person.0675713004.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675713004.57"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2008-05", 
    "datePublishedReg": "2008-05-01", 
    "description": "Cytoreductive nephrectomy (CN) has an established role against metastatic renal cell carcinoma (mRCC) in properly selected patients and offers a survival advantage when performed prior to cytokine therapy. With the emergence of new, effective targeted molecular therapies for mRCC, well-designed prospective trials are needed to clarify the biologic effects of CN to determine when and for whom CN should be performed in the context of targeted systemic therapy. Consequently, a thorough characterization of the systemic effects afforded by CN is imperative for developing individualized treatment strategies that effectively address the underlying biology of mRCC while maximizing patient quality of life during therapy. Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11912-008-0038-3", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438826", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1021174", 
        "issn": [
          "1523-3790", 
          "1534-6269"
        ], 
        "name": "Current Oncology Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "cytoreductive nephrectomy", 
      "systemic therapy", 
      "effective targeted molecular therapy", 
      "renal cell carcinoma", 
      "targeted molecular therapies", 
      "tyrosine kinase inhibitors", 
      "prospective trial", 
      "survival benefit", 
      "select patients", 
      "patients' quality", 
      "cell carcinoma", 
      "treatment strategies", 
      "survival advantage", 
      "systemic effects", 
      "molecular therapy", 
      "therapy", 
      "biologic effects", 
      "patients", 
      "kinase inhibitors", 
      "nephrectomy", 
      "surgery", 
      "carcinoma", 
      "trials", 
      "current status", 
      "inhibitors", 
      "status", 
      "effect", 
      "life", 
      "role", 
      "benefits", 
      "quality", 
      "strategies", 
      "biology", 
      "thorough characterization", 
      "emergence", 
      "era", 
      "characterization", 
      "advantages", 
      "context"
    ], 
    "name": "Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors", 
    "pagination": "253", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033049449"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11912-008-0038-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18765156"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11912-008-0038-3", 
      "https://app.dimensions.ai/details/publication/pub.1033049449"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_457.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11912-008-0038-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11912-008-0038-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11912-008-0038-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11912-008-0038-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11912-008-0038-3'


 

This table displays all metadata directly associated to this object as RDF triples.

153 TRIPLES      20 PREDICATES      74 URIs      65 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11912-008-0038-3 schema:about N0588aa19ff4542c3b306515bcbf85668
2 N391f9c6b93f34539bd3952bcd4a333c5
3 N497e123e824d4e71a3d1b9fcb9b0b71b
4 N6c827039739e49acbb2113ffd320bf87
5 N7f3c2d9611fb45c4a0ce836ea494f79e
6 Ne1ecde88625f4ceab0be72d4773975ec
7 Nfb5e147076604425888f6dcb5b1ecd04
8 anzsrc-for:11
9 anzsrc-for:1103
10 anzsrc-for:1112
11 schema:author Na4cf802d06d142a4a980b047412ae01d
12 schema:datePublished 2008-05
13 schema:datePublishedReg 2008-05-01
14 schema:description Cytoreductive nephrectomy (CN) has an established role against metastatic renal cell carcinoma (mRCC) in properly selected patients and offers a survival advantage when performed prior to cytokine therapy. With the emergence of new, effective targeted molecular therapies for mRCC, well-designed prospective trials are needed to clarify the biologic effects of CN to determine when and for whom CN should be performed in the context of targeted systemic therapy. Consequently, a thorough characterization of the systemic effects afforded by CN is imperative for developing individualized treatment strategies that effectively address the underlying biology of mRCC while maximizing patient quality of life during therapy. Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy.
15 schema:genre article
16 schema:isAccessibleForFree false
17 schema:isPartOf N23f52619f2f74f87b528253a2a445e14
18 Ncbccb37c22d145518dabdeaea21e7086
19 sg:journal.1021174
20 schema:keywords advantages
21 benefits
22 biologic effects
23 biology
24 carcinoma
25 cell carcinoma
26 characterization
27 context
28 current status
29 cytoreductive nephrectomy
30 effect
31 effective targeted molecular therapy
32 emergence
33 era
34 inhibitors
35 kinase inhibitors
36 life
37 metastatic renal cell carcinoma
38 molecular therapy
39 nephrectomy
40 patients
41 patients' quality
42 prospective trial
43 quality
44 renal cell carcinoma
45 role
46 select patients
47 status
48 strategies
49 surgery
50 survival advantage
51 survival benefit
52 systemic effects
53 systemic therapy
54 targeted molecular therapies
55 therapy
56 thorough characterization
57 treatment strategies
58 trials
59 tyrosine kinase inhibitors
60 schema:name Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors
61 schema:pagination 253
62 schema:productId N4a5f6b38eea346f992dfa7b531369b8d
63 N6b69bcb098034eccaff146d585f42763
64 N8895ad352e1c459d8fc5dfbab5531c59
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033049449
66 https://doi.org/10.1007/s11912-008-0038-3
67 schema:sdDatePublished 2022-09-02T15:52
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher Nf3036a0d51ca4be3b3d6d55eff7c7b0c
70 schema:url https://doi.org/10.1007/s11912-008-0038-3
71 sgo:license sg:explorer/license/
72 sgo:sdDataset articles
73 rdf:type schema:ScholarlyArticle
74 N0588aa19ff4542c3b306515bcbf85668 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Combined Modality Therapy
76 rdf:type schema:DefinedTerm
77 N064cce66043b455a8d2e9d7ab58875c9 rdf:first sg:person.01172764022.37
78 rdf:rest N932b016089ad477c94a352e221828101
79 N23f52619f2f74f87b528253a2a445e14 schema:issueNumber 3
80 rdf:type schema:PublicationIssue
81 N391f9c6b93f34539bd3952bcd4a333c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Protein Kinase Inhibitors
83 rdf:type schema:DefinedTerm
84 N391fa84b1efb42139f510171e70ecfba rdf:first sg:person.01040121722.56
85 rdf:rest N064cce66043b455a8d2e9d7ab58875c9
86 N497e123e824d4e71a3d1b9fcb9b0b71b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Humans
88 rdf:type schema:DefinedTerm
89 N4a5f6b38eea346f992dfa7b531369b8d schema:name pubmed_id
90 schema:value 18765156
91 rdf:type schema:PropertyValue
92 N6b69bcb098034eccaff146d585f42763 schema:name dimensions_id
93 schema:value pub.1033049449
94 rdf:type schema:PropertyValue
95 N6c827039739e49acbb2113ffd320bf87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Carcinoma, Renal Cell
97 rdf:type schema:DefinedTerm
98 N7f3c2d9611fb45c4a0ce836ea494f79e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Kidney Neoplasms
100 rdf:type schema:DefinedTerm
101 N8895ad352e1c459d8fc5dfbab5531c59 schema:name doi
102 schema:value 10.1007/s11912-008-0038-3
103 rdf:type schema:PropertyValue
104 N932b016089ad477c94a352e221828101 rdf:first sg:person.0675713004.57
105 rdf:rest rdf:nil
106 Na4cf802d06d142a4a980b047412ae01d rdf:first sg:person.0700013535.70
107 rdf:rest N391fa84b1efb42139f510171e70ecfba
108 Ncbccb37c22d145518dabdeaea21e7086 schema:volumeNumber 10
109 rdf:type schema:PublicationVolume
110 Ne1ecde88625f4ceab0be72d4773975ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Nephrectomy
112 rdf:type schema:DefinedTerm
113 Nf3036a0d51ca4be3b3d6d55eff7c7b0c schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 Nfb5e147076604425888f6dcb5b1ecd04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Clinical Trials as Topic
117 rdf:type schema:DefinedTerm
118 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
119 schema:name Medical and Health Sciences
120 rdf:type schema:DefinedTerm
121 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
122 schema:name Clinical Sciences
123 rdf:type schema:DefinedTerm
124 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
125 schema:name Oncology and Carcinogenesis
126 rdf:type schema:DefinedTerm
127 sg:grant.2438826 http://pending.schema.org/fundedItem sg:pub.10.1007/s11912-008-0038-3
128 rdf:type schema:MonetaryGrant
129 sg:journal.1021174 schema:issn 1523-3790
130 1534-6269
131 schema:name Current Oncology Reports
132 schema:publisher Springer Nature
133 rdf:type schema:Periodical
134 sg:person.01040121722.56 schema:familyName Wood
135 schema:givenName Christopher G.
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
137 rdf:type schema:Person
138 sg:person.01172764022.37 schema:familyName Jonasch
139 schema:givenName Eric
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172764022.37
141 rdf:type schema:Person
142 sg:person.0675713004.57 schema:affiliation grid-institutes:grid.240145.6
143 schema:familyName Matin
144 schema:givenName Surena F.
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675713004.57
146 rdf:type schema:Person
147 sg:person.0700013535.70 schema:familyName Margulis
148 schema:givenName Vitaly
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700013535.70
150 rdf:type schema:Person
151 grid-institutes:grid.240145.6 schema:alternateName Department of Urology, Unit 1373, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA
152 schema:name Department of Urology, Unit 1373, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA
153 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...